Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Biopsy and Mutation Detection Strategies in Non-Small Cell Lung Cancer

  • Jung, Chi Young (Department of Internal Medicine, Keimyung University School of Medicine)
  • Received : 2013.08.21
  • Accepted : 2013.09.04
  • Published : 2013.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

The emergence of new therapeutic agents for non-small cell lung cancer (NSCLC) implies that histologic subtyping and molecular predictive testing are now essential for therapeutic decisions. Histologic subtype predicts the efficacy and toxicity of some treatment agents, as do genetic alterations, which can be important predictive factors in treatment selection. Molecular markers, such as epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement, are the best predictors of response to specific tyrosine kinase inhibitor treatment agents. As the majority of patients with NSCLC present with unresectable disease, it is therefore crucial to optimize the use of tissue samples for diagnostic and predictive examinations, particularly for small biopsy and cytology specimens. Therefore, each institution needs to develop a diagnostic approach requiring close communication between the pulmonologist, radiologist, pathologist, and oncologist in order to preserve sufficient biopsy materials for molecular analysis as well as to ensure rapid diagnosis. Currently, personalized medicine in NSCLC is based on the histologic subtype and molecular status. This review summarizes strategies for tissue acquisition, histologic subtyping and molecular analysis for predictive testing in NSCLC.

Keywords

References

  1. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51. https://doi.org/10.1200/JCO.2007.15.0375
  2. Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:64-70. https://doi.org/10.1097/JTO.0b013e3181f7c6d4
  3. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. https://doi.org/10.1056/NEJMoa061884
  4. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Non-small cell lung cancer version 2.2013 [Internet]. Fort Washington: National Comprehensive Cancer Network; 2013 [cited 2013 Aug 19]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#nscl.
  5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. https://doi.org/10.1056/NEJMoa0810699
  6. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42. https://doi.org/10.1016/S1470-2045(11)70184-X
  7. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010;363:1693-703. https://doi.org/10.1056/NEJMoa1006448
  8. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85. https://doi.org/10.1097/JTO.0b013e318206a221
  9. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 2013;137:668-84. https://doi.org/10.5858/arpa.2012-0263-RA
  10. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-59. https://doi.org/10.1097/JTO.0b013e318290868f
  11. Thunnissen E, Kerr KM, Herth FJ, Lantuejoul S, Papotti M, Rintoul RC, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples: practical approach of a working group. Lung Cancer 2012;76:1-18. https://doi.org/10.1016/j.lungcan.2011.10.017
  12. Moreira AL, Thornton RH. Personalized medicine for nonsmall-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. Clin Lung Cancer 2012;13:334-9. https://doi.org/10.1016/j.cllc.2012.01.004
  13. Rivera MP, Mehta AC; American College of Chest Physicians. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3Suppl):131S-48S. https://doi.org/10.1378/chest.07-1357
  14. Kulesza P, Ramchandran K, Patel JD. Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. Am J Clin Pathol 2011;136:228-38. https://doi.org/10.1309/AJCPO66OIRULFNLZ
  15. Alsharif M, Carlo-Demovich J, Massey C, Madory JE, Lewin D, Medina AM, et al. Telecytopathology for immediate evaluation of fine-needle aspiration specimens. Cancer Cytopathol 2010;118:119-26. https://doi.org/10.1002/cncy.20074
  16. Navani N, Brown JM, Nankivell M, Woolhouse I, Harrison RN, Jeebun V, et al. Suitability of endobronchial ultrasoundguided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med 2012;185:1316-22. https://doi.org/10.1164/rccm.201202-0294OC
  17. Sakairi Y, Nakajima T, Yasufuku K, Ikebe D, Kageyama H, Soda M, et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasoundguided transbronchial needle aspiration. Clin Cancer Res 2010;16:4938-45. https://doi.org/10.1158/1078-0432.CCR-10-0099
  18. Aisner DL, Marshall CB. Molecular pathology of nonsmall cell lung cancer: a practical guide. Am J Clin Pathol 2012;138:332-46. https://doi.org/10.1309/AJCPFR12WJKCEEZZ
  19. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010;5:442-7. https://doi.org/10.1097/JTO.0b013e3181d40fac
  20. Mukhopadhyay S, Katzenstein AL. Subclassification of nonsmall cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35:15-25. https://doi.org/10.1097/PAS.0b013e3182036d05
  21. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. https://doi.org/10.1056/NEJMoa040938
  22. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81. https://doi.org/10.1038/nrc2088
  23. Kim WS, Choi YD, Seo JW, Han JH, Kim MJ, Kim L, et al. Epidermal growth factor receptor mutation analysis of non-small cell lung cancer in South Korea: summary from a nationwide survey. J Lung Cancer 2010;9 Suppl 2:S38.
  24. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013;8:52-61. https://doi.org/10.1097/JTO.0b013e3182769aa8
  25. Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 2013;66:79-89. https://doi.org/10.1136/jclinpath-2012-201194
  26. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007;13:4954-5. https://doi.org/10.1158/1078-0432.CCR-07-1387
  27. Kawahara A, Taira T, Azuma K, Tominaga M, Hattori S, Kawahara M, et al. A diagnostic algorithm using EGFR mutationspecific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Lung Cancer 2012;78:39-44. https://doi.org/10.1016/j.lungcan.2012.07.002
  28. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. https://doi.org/10.1038/nature05945
  29. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203. https://doi.org/10.1016/j.cell.2007.11.025
  30. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009;4:1450-4. https://doi.org/10.1097/JTO.0b013e3181c4dedb
  31. Murakami Y, Mitsudomi T, Yatabe Y. A screening method for the ALK fusion gene in NSCLC. Front Oncol 2012;2:24.
  32. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53. https://doi.org/10.1200/JCO.2009.22.6993
  33. Weickhardt AJ, Aisner DL, Franklin WA, Varella-Garcia M, Doebele RC, Camidge DR. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer 2013;119:1467-77. https://doi.org/10.1002/cncr.27913
  34. Marchetti A, Ardizzoni A, Papotti M, Crino L, Rossi G, Gridelli C, et al. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. J Thorac Oncol 2013;8:352-8. https://doi.org/10.1097/JTO.0b013e31827d5280
  35. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011;6:466-72. https://doi.org/10.1097/JTO.0b013e31820b82e8
  36. Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012;76:403-9. https://doi.org/10.1016/j.lungcan.2011.11.008

Cited by

  1. Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma vol.29, pp.6, 2014, https://doi.org/10.1097/rti.0000000000000116
  2. Current and future molecular diagnostics in non-small-cell lung cancer vol.15, pp.8, 2013, https://doi.org/10.1586/14737159.2015.1063420
  3. New immunohistochemical markers in the differential diagnosisof nonsmall cell lung carcinoma vol.46, pp.6, 2013, https://doi.org/10.3906/sag-1501-68
  4. A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patients vol.15, pp.6, 2013, https://doi.org/10.3892/mmr.2017.6530